Delisting riskPopularity #5,220
BGM · NASDAQ · Drug Manufacturers - Specialty & Generic

BGM Group (BGM)

Combines pharmaceutical production with AI solutions and insurance services for Chinese markets.

$0.2650
After hours+0.01 (+5.12%)
At close$0.2521(−1.52%)
Loading prices…

BGM Group Ltd.BGM
Health Care

Produces pharmaceutical and allied products while supplying AI solutions and insurance services in China. The Cayman holding company operates through PRC subsidiaries and a consolidated VIE, with newer technology activities added through recent transactions.

Produces oxytetracycline API, crude heparin sodium and licorice preparations through its biopharmaceutical division, alongside diversified pharmaceutical and allied products. AI solutions and insurance business are additional reported activities, serving insurance companies, brokers and consumers through sales, underwriting, claims and customer-service workflows.

Operates in China through subsidiaries and a consolidated VIE under a Cayman Islands holding company. Du Xiao Bao and Bao Wang use data mining and AI-agent technology for insurance-oriented solutions, while the company also focuses on intelligent robots, algorithmic computing power, cloud computing and biopharmaceuticals. Its structure depends on contractual VIE arrangements whose enforceability and regulatory treatment under PRC law remain uncertain.

Company facts

CEOHuandi Zhao
ListedJan 12, 2021
ExchangeNASDAQ
HeadquartersChengdu, China
CountryChina
Employees463
CIK0001779578
ISINKYG7307E1237

Market cap$97.4M
EPS (ttm)−$0.1613
P/E (ttm)−1.59
ROE-5.4%
P/B0.2447
P/S2.03
Dividend yieldDiv yield
Beta1.01vs XLV −0.59

No analyst consensus on record.

EPSReportedEstimate

May '24Mar '26
Reported$0.05
Estimate
Surprise

RevenueReportedEstimate

May '24Mar '26
Reported$12.6M$23.6M
Estimate
Surprise
Estimate
Reported
Estimate
Reported$23.6M
View details

Debt to equity0.30%
Current ratio125.00%

ProfitabilityRevenueNet incomeNet margin

Q2 FY24Q2 FY25Q4 FY25Q2 FY26
Revenue$12.6M$14.3M$23.6M$24.3M
Net income$328.8K−$861.2K−$19.1M−$2.1M
Net margin2.6%0.0%0.0%0.0%

GrowthOperating income

Q2 FY24Q2 FY25Q4 FY25Q2 FY26
Operating income−$679.1K−$2.2M−$10.3M−$877.9K
YoY growthLoss widenedLoss narrowed

Balance sheet, Mar 31, 2026Cash & short-term investments $11.5M · Total debt $1.2M · Total assets $436.5M · Shareholders' equity $398.2M

Revenue
$24.3M
Operating income
−$877.9K
Net income
−$2.1M
View details

Dividend yield
Next ex-date
Annual dividend
Schedule

HistoryDividend

Feb '23
Dividend$0.25
Ex-dateFeb 27
Payment dateMar 6
View details

Institutions0.10%377.3K shares
12 holders · as of Jun 30, 2026
Other99.90%380.25M shares
remainder

380.62M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
Geode Capital Management, LLCInstitution
0.03%98,472as of Jun 30, 2026
XTX Topco LtdInstitution
0.02%63,089as of Jun 30, 2026
UBS Group AGInstitution
0.02%57,646as of Jun 30, 2026
Jane Street Group, LLCInstitution
0.02%57,227as of Jun 30, 2026
Virtu Financial LLCInstitution
0.01%54,207as of Jun 30, 2026

Insider tradesForm 4

Nothing filed in the last 12 months.

View details

CompareAfter hours

CompanyPriceChange
BGM Group$0.2650+5.12%$97.4M2.0
Waterdrop (ADR)$1.050.00%$383.4M0.70.5+82.4%
Median0.70.5+82.4%